Advertisement
Advertisement
Rocket Pharma’s Gene Therapy Study for Danon Disease: A Potential Game-Changer
PremiumCompany AnnouncementsRocket Pharma’s Gene Therapy Study for Danon Disease: A Potential Game-Changer
19d ago
Rocket Pharma’s PKP2-ACM Study: A Step Forward in Cardiomyopathy Research
Premium
Company Announcements
Rocket Pharma’s PKP2-ACM Study: A Step Forward in Cardiomyopathy Research
19d ago
Rocket Pharma’s New Gene Therapy Trial: A Potential Game-Changer for Cardiomyopathy
Premium
Company Announcements
Rocket Pharma’s New Gene Therapy Trial: A Potential Game-Changer for Cardiomyopathy
19d ago
Cautious Hold Rating on Rocket Pharmaceuticals Amid Kresladi Developments and Danon Disease Uncertainty
PremiumRatingsCautious Hold Rating on Rocket Pharmaceuticals Amid Kresladi Developments and Danon Disease Uncertainty
1M ago
Rocket Pharmaceuticals’ FDA Resubmission for KRESLADI™ Accepted
Premium
Company Announcements
Rocket Pharmaceuticals’ FDA Resubmission for KRESLADI™ Accepted
1M ago
Rocket Pharmaceuticals announces FDA acceptance of Kresladi BLA resubmission
Premium
The Fly
Rocket Pharmaceuticals announces FDA acceptance of Kresladi BLA resubmission
1M ago
Hold Rating on Rocket Pharmaceuticals Amid Strategic Shifts and Regulatory Challenges
PremiumRatingsHold Rating on Rocket Pharmaceuticals Amid Strategic Shifts and Regulatory Challenges
1M ago
Rocket Pharmaceuticals withdraws BLA for Fanskya
Premium
The Fly
Rocket Pharmaceuticals withdraws BLA for Fanskya
1M ago
Rocket Pharmaceuticals Withdraws FDA Application for Gene Therapy
Premium
Company Announcements
Rocket Pharmaceuticals Withdraws FDA Application for Gene Therapy
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100